Similar companies
Income Statement (NONE)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 5.54B | 2.6% |
| Gross Profit | 5.27B | 1.1% |
| Cost of Revenue | 273M | 43.7% |
| Operating expense | 3.17B | 6.8% |
| Net Income | 1.27B | 10.1% |
| EBITDA | 1.85B | 13.8% |
Balance Sheet (NONE)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 39.7B | 2.7% |
| Total Liabilities | 7.74B | 1.2% |
| Total Equity | 31.9B | 3.1% |
| Shares Outstanding | 649M | 0% |
Cash Flow (NONE)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | 2.03B | 34.4% |
| Cash from financing | -276M | 91% |
Financial Highlights for Genmab A/S in Q3 '24
Genmab A/S reported a revenue of 5.54B, which is a 2.6% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 5.27B, marking a 1.1% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 273M, a 43.7% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 3.17B, showing a -6.8% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 1.27B, showing a -10.1% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 1.85B, showing a -13.8% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Genmab A/S faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. An increase in the cost of revenue, higher than the revenue growth, suggests potential margin pressures. A decline in EBITDA signals potential operational challenges or increased costs.
